vp-0268
print Print Back Back

Empliciti™ (elotuzumab) (Intravenous)

Policy Number: VP-0268

Last Review Date:12/03/2019

Date of Origin: 02/23/2016

Dates Reviewed: 02/2016, 01/2017, 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 09/2018, 12/2018, 03/2019, 09/2019, 12/2019

I. Length of Authorization

Coverage will be provided for 6 months and may be renewed

II. Dosing Limits

  1. Quantity Limit (max daily dose) [NDC Unit]:
  • 300 mg vials: 16 vials per 28 days for 2 cycles; subsequent cycles are 8 vials per 28 days
  • 400 mg vials: 12 vials per 28 days for 2 cycles; subsequent cycles are 6 vials per 28 days
  1. Max Units (per dose and over time) [HCPCS Unit]:

Given in combination with Lenalidomide/Dexamethasone:

  • 1200 billable units weekly for the first two 28-day cycles (8 doses), then every two weeks thereafter beginning D1 of cycle 3

Given in combination with Pomalidomide/Dexamethasone:

  • 1200 billable units weekly for the first two 28-day cycles (8 doses), then 2300 billable units every four weeks thereafter beginning D1 of cycle 3

III. Initial Approval Criteria

Coverage is provided in the following conditions:

  • Patient is 18 years or older; AND

Multiple myeloma †

  • Patient has a diagnosis of relapsed or progressive disease; AND
    • Used in combination with lenalidomide and dexamethasone after failure of one to three prior therapies; OR
    • Used in combination with pomalidomide and dexamethasone after failure of at least two prior therapies, including immunomodulatory agent [i.e., lenalidomide] and a proteasome inhibitor [i.e., bortezomib, carfilzomib, etc].; OR
    • Used in combination with bortezomib and dexamethasone

FDA Approved Indication(s); Compendia recommended indication(s)

IV. Renewal Criteria

Coverage can be renewed based upon the following criteria:

  • Patient continues to meet the criteria identified in section III; AND
  • Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; AND
  • Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe infusion reactions, infections, second primary malignancies, hepatotoxicity, etc.

V. Dosage/Administration

Indication

Dose

In combination with lenalidomide and dexamethasone

10 mg/kg intravenously every week (D1, D8, D15, & D22) for the first two 28-day cycles (8 doses); then every 2 weeks thereafter (D1 & D15) beginning with cycle 3

  • Lenalidomide 25 mg orally daily Days 1-21
  • Oral dexamethasone 28 mg given weekly when elotuzumab is also given & 40 mg on weeks elotuzumab is not given
  • Intravenous dexamethasone 8 mg given weekly when elotuzumab is given

In combination with pomalidomide and dexamethasone

10 mg/kg intravenously every week (D1, D8, D15, & D22) for the first two 28-day cycles (8 doses); then 20 mg/kg every 4 weeks thereafter (D1) beginning with cycle 3

 

  • Patients ≤ 75 years old:
  • Pomalidomide 4 mg orally daily Days 1-21
  • Oral dexamethasone 28 mg given weekly when elotuzumab is also given & 40 mg on weeks elotuzumab is not given)
  • Intravenous dexamethasone 8 mg given weekly when elotuzumab is also given
  • Patients > 75 years old:
  • Pomalidomide 4 mg orally daily Days 1-21
  • Oral dexamethasone 8 mg given weekly when elotuzumab is also given & 20 mg on weeks elotuzumab is not given
  • Intravenous dexamethasone 8 mg given weekly when elotuzumab is also given

Multiple myeloma in combination with bortezomib and dexamethasone

10 mg/kg intravenously weekly for cycles 1 and 2, on days 1 and 11 for cycles 3 to 8, and then on days 1 and 15 thereafter

  • Bortezomib (1.3 mg/m2 IV or subcutaneously) administered on days 1, 4, 8, and 11 for cycles 1 to 8 and then on days 1, 8, and 15 thereafter
  • Dexamethasone 20 mg administered orally on non-elotuzumab dosing days, and as 8 mg orally plus 8 mg IV on elotuzumab dosing days

VI. Billing Code/Availability Information

HCPCS code:

  • J9176 - Injection, elotuzumab, 1 mg; 1 billing unit = 1 mg

NDC(s):

  • Empliciti 300 mg single-dose vial: 00003-2291-xx
  • Empliciti 400 mg single-dose vial: 00003-4522-xx
  1. References
  1. Empliciti [package insert]. Princeton, NJ; Bristol-Myers Squibb Company; November 2018. Accessed October 2019.
  2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for elotuzumab. National Comprehensive Cancer Network, 2019. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed October 2019.
  3. Jakubowiak A, Offidani M, Pégourie B, et al. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 Jun 9;127(23):2833-40.
  4. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.
  5. Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.
  6. CGS Administrators, LLC. Local Coverage Article: Billing and Coding: Elotuzumab (EMPLICITI) -J9176 (A57246). Centers for Medicare and Medicaid Services, Inc. Updated on 9/18/2019 with effective date 09/26/2019. Accessed October 2019.
  7. Palmetto GBA, LLC. Local Coverage Article: Billing and Coding: Chemotherapy (A56141). Centers for Medicare and Medicaid Services, Inc. Updated on 08/12/2019 with effective date 08/22/2019. Accessed October 2019.

Appendix 1 – Covered Diagnosis Codes

ICD-10

ICD-10 Description

C90.00

Multiple myeloma not having achieved remission

C90.02

Multiple myeloma, in relapse

C90.10

Plasma cell leukemia not having achieved remission

C90.12

Plasma cell leukemia in relapse

C90.20

Extramedullary plasmacytoma not having achieved remission

C90.22

Extramedullary plasmacytoma in relapse

C90.30

Solitary plasmacytoma not having achieved remission

C90.32

Solitary plasmacytoma in relapse

Z85.79

Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Articles may exist and compliance with these policies is required where applicable. They can be found at: http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/Article): 

Jurisdiction(s): 15

NCD/LCD/Article Document (s): A57246

https://www.cms.gov/medicare-coverage-database/search/lcd-date-search.aspx?DocID=A57246&bc=gAAAAAAAAAAA

Jurisdiction(s): J & M

NCD/LCD/Article Document (s): A56141

https://www.cms.gov/medicare-coverage-database/search/lcd-date-search.aspx?DocID=A56141&bc=gAAAAAAAAAAA

 

Medicare Part B Administrative Contractor (MAC) Jurisdictions

Jurisdiction

Applicable State/US Territory

Contractor

E (1)

CA, HI, NV, AS, GU, CNMI

Noridian Healthcare Solutions, LLC

F (2 & 3)

AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ

Noridian Healthcare Solutions, LLC

5

KS, NE, IA, MO

Wisconsin Physicians Service Insurance Corp (WPS)

6

MN, WI, IL

National Government Services, Inc. (NGS)

H (4 & 7)

LA, AR, MS, TX, OK, CO, NM

Novitas Solutions, Inc.

8

MI, IN

Wisconsin Physicians Service Insurance Corp (WPS)

N (9)

FL, PR, VI

First Coast Service Options, Inc.

J (10)

TN, GA, AL

Palmetto GBA, LLC

M (11)

NC, SC, WV, VA (excluding below)

Palmetto GBA, LLC

L (12)

DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)

Novitas Solutions, Inc.

K (13 & 14)

NY, CT, MA, RI, VT, ME, NH

National Government Services, Inc. (NGS)

15

KY, OH

CGS Administrators, LLC